E levations in systolic blood pressure (SBP) and diastolic blood pressure (DBP) are known to be associated with an increased risk of adverse outcomes in chronic kidney disease (CKD). [1] [2] [3] [4] [5] [6] [7] As such, blood pressure (BP) control is an important therapeutic target to aid in the progression of CKD and cardiovascular mortality. 8 Despite a large body of evidence in patients with milder degrees of CKD, there are few studies on the effects of BP in patients with late-stage (estimated glomerular filtration rate [eGFR] <30 mL/min) CKD. 5, [9] [10] [11] BP control and the optimal means of evaluating BP in late-stage CKD remains controversial. Numerous studies report conflicting associations between a single baseline BP and end-stage kidney disease (ESKD) or mortality. 1, 5, 9, 10, 12, 13 In real world clinical practice, physicians often consider multiple, additional scenarios about BP information and their relation to the need for dialysis or mortality. For example, decision-making and changes in pharmacological agents are often determined by the most recent BP value observed in a given clinic visit. However, an earlier BP measurement such as the visit immediately preceding the most recent one (termed lag) may allow for early changes in therapy potentially reducing the risk of an adverse outcome. Physicians may consider averaging all previous BP measures up to the most recent as this may better mimic the temporal effect of hypertension injury on end organs. Last, physicians may consider the ability to achieve and maintain a reasonable level of BP control because entering their care (changes from baseline) as a means to offset adverse outcomes.
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As BP control is crucially important in late-stage CKD, we set out to systematically examine differing methods of accounting for BP and their association with adverse outcomes. Specifically, we examined the association of SBP and Abstract-Whether different methods of quantitating blood pressure (BP) in late chronic kidney disease better mimic pathophysiological processes and clinical outcomes remains unclear. In a retrospective study, we determined the association of BP with end-stage kidney disease (ESKD) and all-cause mortality with BP modeled at baseline versus longitudinally with time-varying Cox models as (1) current (most recent) clinic visit, (2) lag (visit immediately preceding the current), (3) cumulative (average of previous measurements), and (4) change from baseline to the most recent. Among 1203 (6913 visits) study patients, the mean age and baseline estimated glomerular filtration rate were 66 and 18 mL·min ), and 40% were female. Patients had a mean of 6.7 BP measurements, 540 (44.8%) reached ESKD, and 141 (11.7%) died. For systolic BP >160, current (hazard ratio [HR], 1.67), cumulative (HR, 1.58), and a rise to >160 from baseline 120 to 160 (HR, 1.60) were associated with ESKD. Similarly, diastolic BP >85 was associated with ESKD when modeled as current (HR, 1.47), lag (HR, 1.63), cumulative (HR, 2.15), or change from baseline (rise to >85 from a baseline of 60-85; HR, 1.62). Both low SBP (<120), when modeled as current (HR, 1.59), cumulative exposure (HR, 1.76), persistently <120 (HR, 2.28), and high SBP (>140), when modeled as cumulative exposure, were associated with all-cause mortality. For diastolic BP, only cumulative >85 was significantly associated with mortality (HR, 2.75). Thus, in late-stage chronic kidney disease, persistently high or rises in systolic BP or diastolic BP are associated with risk of ESKD, whereas baseline BP measures did not convey information on risk. (Hypertension. 2017;70:1210-1218. DOI:
DBP as a single measure at baseline into cohort entry and as 4 methods accounting for repeat (longitudinal) time-dependent BP measures as follows: (1) current (most recent) clinic visit, (2) lag 1 visit (visit immediately preceding the most recent one), (3) cumulative (average of all previous measurements to date), and (4) change from baseline to the most recent visit with the clinical outcomes of ESKD and all-cause mortality. We hypothesized that longitudinal measures of BP would be more strongly associated with all-cause mortality or ESKD in late-stage CKD patients.
Methods

Study Cohort
This is a retrospective cohort study using prospectively collected data on n=1209 adult patients (>18 years) followed in a hospital CKD clinic from January 2010 to November 2015.
14 The tertiary care, specialty CKD clinic, serves a catchment area of ≈1.2 million individuals in Ottawa, Canada. The clinic is staffed by a multidisciplinary care team, including physicians, nurses, dietitians, pharmacists, and social workers, specializing in patients approaching ESKD. Patients are referred to the clinic by their primary nephrologists in anticipation of ESKD. Timing of transfer is at the discretion of the primary nephrologist with 99% of patients entering the clinic with an eGFR <30 mL·min −1 ·1.73 m −2 (calculated using the modified diet in renal disease formula). The first clinic visit was deemed the date of study entry. Patients are seen in the clinic regularly, sometimes as often as every 2 weeks and at a minimum twice a year, though the exact interval is left to the discretion of the clinician. There are standardized treatment procedures for vaccinations and consensus about anemia, BP targets, and preferred medications, and all patients use a decision aid on modality selection. Patient information was deidentified before analysis. The study was reviewed and approved by the Ottawa Hospital Research Ethics Board.
Data Collection
Data were abstracted from clinical charts and electronic medical records by trained clerks starting January 2010 and validated by random audit of 5% of entries every 6 months with >95% accuracy.
Variables collected include demographics (age, sex, and race), cause of CKD, comorbidities (coronary artery disease, congestive heart failure, diabetes mellitus, peripheral vascular disease, and malignancy), outcomes with dates (death, dialysis initiation) and longitudinal measures of laboratory measures (hemoglobin, phosphate, potassium, bicarbonate, proteinuria, eGFR, and albumin), physiological parameters (BP), and medications. Comorbidities were defined by self-report or clinical documentation based on the medical chart.
Exposures and Outcomes
The main exposures of interest were SBP and DBP. At each clinic visit, resting BP was measured once by a trained nurse using a mercury sphygmomanometer. BP measurements were made with patients in the sitting position, after 5 minutes of rest, with an appropriately fitted BP cuff and the cuff placed directly on the skin.
BP measures (SBP, DBP) were examined at baseline at cohort entry and by 4 longitudinal time-dependent measures current, lag, cumulative, and change from baseline. Time-dependent measures included all values over the follow-up period and examine the association of an outcome and the BP measure taken at the most recent clinic measure. Lag measures examine the association of an outcome and the BP measure from the clinic visit immediately before the most recent measure. Cumulative measures the average all the previous BP measures up to the most recent measurement. Change from baseline examines how subsequent BP measures change relative to the first (baseline) BP measure at cohort entry. The main outcomes of interest for this study were ESKD, defined by the initiation of dialysis or preemptive transplantation (n=8), or all-cause mortality.
Demographics and comorbidities (coronary artery disease, congestive heart failure, malignancy, peripheral vascular disease, and diabetes mellitus) were obtained by clinical history of a previous diagnosis. Cause of CKD was based on the most responsible nephrologists' diagnosis.
Statistical Analysis
The 2-year kidney failure risk equation (model 3: age, sex, eGFR, and the albumin to creatinine ratio) was used to estimate the risk of ESKD. 15 Proteinuria was categorized as minimal (albumin-to-creatinine ratio <30 mg/g, protein-to-creatinine ratio <27 mg/g), mild (albumin-to-creatinine ratio, 30-149 mg/g; protein-to-creatinine ratio, 27-150; 24-hour urine protein <0.3 g/d), moderate (albumin-to-creatinine ratio, 150-350 mg/g; Figure 1 . Creation of the analytic study cohort.
protein-to-creatinine ratio, 151-300 mg/g; 24-hour urine protein, 0.3-3 g/d), or severe (albumin-to-creatinine ratio >350 mg/g, protein-to-creatinine ratio >300 mg/g, 24-hour urine protein >3 g/d). The various SBP and DBP distributions were examined graphically.
We examined the association of BP (SBP and DBP) with ESKD or all-cause mortality separately using time-to-event models. BP was modeled categorically (SBP: <120, 121-140, 141-160, >160; DBP: <60, 60-75, 76-85, >85) as previous studies reported U-shaped associations with BP and outcomes in CKD. 4, 16 Models were created to examine the association of SBP or DBP measures as baseline or as time-dependent measures, where time-dependent measures were expressed as current, lag, cumulative, or change from baseline. All exposures except baseline were analyzed using extended Cox proportional hazards models to account for longitudinal (time-dependent) measures. To examine change from baseline, baseline and subsequent measures of BP were categorized with the number of categories determined by the distribution of events.
All ESKD models were adjusted for age, sex, cause of CKD, comorbidities (coronary artery disease, congestive heart failure, peripheral vascular disease, diabetes mellitus, and malignancy), repeat measures of laboratory values (proteinuria, hemoglobin, albumin, potassium, phosphate, and bicarbonate), baseline eGFR, baseline BP, and the number of antihypertensive medications. All-cause mortality models were adjusted for age, sex, comorbidities (congestive heart failure, diabetes mellitus, and malignancy), baseline BP, and laboratory values (albumin, phosphate). Mortality models examining BP as a change from baseline were adjusted for age, congestive heart failure, albumin, and phosphate as they demonstrated the strongest association with mortality. Model fit was examined by the Akaike information criteria. Patients were censored at the outcomes of interest (n=681), at study end (n=287), at loss to follow-up (n=20), or if they moved out of province (n=33). In a sensitivity analysis, we examined for informative censoring by excluding (1) all observations for patients who died in models when the outcome was ESKD and (2) all observations for patients who reached ESKD in models when the outcome was death.
To avoid exclusion of subjects because of missing covariates, multiple imputation was performed before analysis. The imputations were generated using a Markov Chain Monte Carlo algorithm (the data augmentation algorithm). 17 Ten multiple imputation data sets were generated with all variables included in analytic models specified as predictors in the multiple imputation model. 18 Analyses were performed for each multiple imputation data set and pooled across data sets using Rubin rules. All analyses were conducted with SAS 9.4.
Results
Study Cohort
Our cohort included N=1203 adult patients (>18 years) comprising a total of 6123 unique observations (Figure 1) . Study exclusions were patients followed for <30 days (n=6 patients, 11 observations), and observations after 4 years (n=143). The median follow-up time was 1.49 (interquartile range, 0.8-2.45) years and time between visits 101 (range, 30-727) days. The mean (range) of number of BP measures per patient were 6.7 (range, 1-17) with 98% of patients having ≥2 measures. Missing data were all <6% of measures with the exception being proteinuria at 19.7%.
The median eGFR at first clinic visit was 17.77 mL·min (Table 1 ). The mean patient age at cohort entry was 65.6 years. The majority of patients were white, men with a mean body mass index of 30.1. The most common identified causes of CKD were diabetes mellitus, ischemic nephropathy, and glomerulonephritis. Hypertension, diabetes mellitus, and cardiac disease were common comorbidities and nearly half of patients were on renal artery stenosis blockade at cohort entry. The degree of proteinuria was evenly distributed across categories with the highest proportion in those with severe proteinuria. Nearly one-third of patients had a 2-year kidney failure risk of >15% by the kidney failure risk equation.
The baseline distribution of SBP was <120 (18%), 121 to 140 (39.7%), 141 to 160 (26.4%), and >160 (16.0%) and for DBP was <60 (21.5%), 60 to 75 (39.8%), 76 to 85 (24.4%), and >85 (14.3%) in mm Hg. For most current measure, SBP and DBP, roughly 70% of measures were between SBP 120 to 160 and DBP 60 to 85. This was similar for lag BP measures. For cumulative BPs, there were fewer patients with extremes of SBP (>160) or DBP (>85) with <5% of participants in these categories by 1 year of follow-up. For BP changes from baseline, the majority were within the ranges of SBP 121 to 160 or DBP 60 to 85. Figure 2 and The crude number of events and estimated HRs for each type of exposure (expressed as baseline, current, lag, cumulative, and change from baseline) with all-cause mortality are presented in Table 3 for SBP and Table 4 for DBP. As for ESKD, neither baseline SBP or DBP were significantly associated with mortality. Covariates associated with mortality in the time-varying models included albumin, age, baseline eGFR, baseline BP, congestive heart failure, malignancy (all P<0.001), hemoglobin (P=0.04), and phosphate (P=0.03). Current SBP <120 was significantly associated with mortality in the time-dependent model (HR, 1.59; 95% CI, 1.04-2.44; referent SBP, 121-140), the cumulative model (HR, 1.76; 95% CI, 1.10-2.82; referent SBP, 121-140), and if persistently low (HR, 2.28; 95% CI, 1.38-3.77; referent SBP, 120-140). Cumulative SBP >140 was significantly associated with mortality in a dose-dependent manner (SBP, 141-160; HR, 1.63; 95% CI, 1.02-2.62; SBP>160, HR, 3.03; 95% CI, 1.34-6.87; referent, 120-140). Only cumulative DBP >85 was significantly associated with mortality (HR, 2.75; 95% CI, 1.05-7.20) albeit in a small number of events (n=6). In a sensitivity analysis excluding patients with ESKD, there were slight changes in the point estimates for the association of SBP/DBP with all-cause mortality for the current, lag, and cumulative models (Table S1 ). However, the overall trend of the point estimates was similar and the changes were within the CIs of the original estimates. For the change from baseline model, the HR increased from 2.85 to 2.28 for patients with baseline SBP <120 and change <120 (results not shown). Model fit was lowest for the cumulative models for both SBP (Akaike information criteria 1572) and DBP (Akaike information criteria 1578; Table S2 ).
Association of SBP and DBP Modeled as Baseline and
Time-Dependent Exposures (Current, Lag, Cumulative, and Change From Baseline) With ESKD The crude number of events and estimated hazard ratios (HRs) for each type of exposure (expressed as baseline, most recent, lag, cumulative, and change from baseline) with ESKD are presented in
Discussion
In a unique cohort of late-stage CKD patients followed longitudinally in an outpatient clinic, we examined the association of differing repeat measures of SBP and DBP exposure with ESKD and all-cause mortality. We found elevations in SBP and DBP to be consistently associated with ESKD, whereas persistently low or cumulatively high SBP were associated with all-cause mortality. For SBP >160 mm Hg, time-dependent measures (current, cumulative, and rises in SBP from baseline) were significantly associated with ESKD, whereas for DBP all longitudinal measures >85 mm Hg were associated with ESKD. Most longitudinal measures of SBP <120 mm Hg and cumulative SBP >140 were associated with mortality. Baseline BP measures were not significantly associated with any outcomes. Interestingly, for patients with more moderate ranges of SBP (121-140 mm Hg) or DBP (60-85 mm Hg) at baseline, a subsequent rise >160 mm Hg or >85 mm Hg was associated with an increased risk of ESKD. Furthermore, DBP >85 mm Hg, on the previous second last clinic visit (lag), was associated with a higher ESKD risk suggesting the possibility of therapeutic interventions as a means of reducing the ESKD risk. The results were consistent when accounting for informative censoring. Overall, these findings demonstrate for patients with late-stage CKD, that the risk of ESKD or mortality is significantly associated with longitudinal BP measures with the differing means of quantitating BP conferring additional and potentially useful information. In our comprehensive assessment of longitudinal BP measures, we found thresholds for BP values and adverse clinical outcomes that are consistent with previous studies in CKD.
Hanratty et al 19 examined the association of SBP and incident CKD in 43 305 patients at a private healthcare network. They found a time-weighted higher SBP to be associated with eGFR decline and the cumulative incidence of CKD started to increase with a time-varying SBP >140 mm Hg. Anderson et al 20 reported data on 3708 patients with CKD from the CRIC (Chronic Renal Insufficiency Cohort) with a baseline mean eGFR of 45 mL/min. They found a greater than doubling in the adjusted risk of ESKD when examining repeat measures of SBP ≥140 mm Hg compared with baseline (HR repeat measures, 3.37 versus HR baseline, 1.46) using marginal structural models. Marginal structural models uses inverse probability of treatment weighting to provide average casual treatment effects. Our study differs from previous studies as we examined a broader array of methods for quantitating BP exposures and we examined this relationship in late-stage CKD (eGFR <30). Nevertheless, in our study we identified similar SBP thresholds associated with ESKD risk with SBP >160 mm Hg. CI indicates confidence interval; HR, hazard ratio; and SBP, systolic blood pressure. All models adjusted for age, sex, comorbidities (congestive heart failure, diabetes mellitus, and malignancy), laboratory values (albumin, phosphate), and baseline BP except * that was adjusted for age, congestive heart failure, albumin, phosphate, and baseline BP only.
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To our knowledge, ours is the first study to report the consistent association between longitudinal DBP and ESKD. Previous studies report conflicting results about the association between DBP and ESKD. [1] [2] [3] 5, 9, 12 We found DBP >85 mm Hg to be consistently and strongly associated with ESKD across a range of different models with adjusted hazards ranging from 1.5 to 2.2 (referent DBP, 60-75 mm Hg). Whether this finding is specific to the late-stage CKD population requires further investigation.
A higher ESKD risk with a rise in BP from baseline is a unique and novel observation. CKD patients who enter the speciality clinic with BPs in more conventional ranges (SBP, 120-160 mm Hg; DBP, 60-85 mm Hg) with subsequent measures that rise are at a higher ESKD risk. The association of higher BP and ESKD has been reported previously with the traditional paradigm being elevations in BP accelerate end-organ damage and the progression of CKD. However, we demonstrated the relationship between BP and ESKD in CKD is more complex as a late rise in BP is associated with ESKD onset. This raises the intriguing possibility of reverse causality as the rise in BP may be a sign of increasing extracellular fluid volume expansion with declining kidney function. A rise in BP is known to increase the risk of adverse events in the general population. Verdecchia et al 21 reported a rise from baseline BP to be associated with stroke and myocardial infarction in 25 620 patients from the ONTARGET cohort (Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial). 21 The importance of a rising DBP is reinforced by the observation that a lag DBP (the measure before the last clinic visit) >75 mm Hg is associated with ESKD. In the general population, a reduction from baseline BP is associated with a reduction in stroke risk, but we did not observe any benefit from a reduction of moderate baseline BP to subsequent lower levels on ESKD or all-cause mortality. 21 These observations are highly clinically relevant, as a rise in BP should prompt consideration of imminent ESKD. Furthermore, interventions to lower a rising BP in late-stage CKD as a means of delaying ESKD remain a possibility and warrant further investigation. Similarly, we demonstrated a U-shaped association of SBP and all-cause mortality, however, it was based on the method of quantitation for SBP. Low and high SBP were consistently associated with higher mortality in models accounting for cumulative exposure illustrating the importance of temporality on the association. In our sensitivity analysis, after exclusion of patients who reached ESKD, the risk of all-cause mortality for baseline SBP< 120 and repeat SBP <120 increased from 2.28 to 2.85. In contrast, in the ESKD model excluding patients who died the HR remained similar demonstrating a lower ESKD risk. These findings suggest that patients with persistently low SBP are heterogeneous with some demonstrating a protective benefit, whereas in others, it is a sign of poor health.
Previous studies have demonstrated conflicting results on the importance and use of differing longitudinal exposures in chronic disease. Wald et al 22 examined abnormalities in mineral metabolism in 1846 chronic hemodialysis patients. Cumulative measures of calcium and phosphorous were more consistently associated with clinical outcomes than timedependent or baseline measures. Reinikainen et al 23 examined differing quantitation of risk factors and their association with cardiovascular mortality in a longitudinally followed cohort of 1711 men. Models incorporating cumulative risk factors demonstrated better discrimination relative to time-dependent models. Hanratty et al 19 reported associations between SBP and incidence of CKD quantitating SBP separately as baseline, time-dependent and time-weighted exposures (cumulative) demonstrating associations with all 3 methods in a cohort of patients with mild CKD. In contrast, Barbour et al 24 examining different longitudinal exposures for proteinuria reporting timedependant measures to best prognosticate clinical outcomes in glomerulonephritis. We demonstrated the strongest associations with cumulative exposures to longitudinal BP with no baseline BP measures demonstrating statistical significance.
Strengths of our study include a unique cohort of real world late-stage CKD patients, multiple BP measures per patient, the use of a validated database, the large number of covariates adjusted for in our analyses and methodology that accounts for differing longitudinal measures of BP exposure. Our study did have some potential limitations. Despite over 10 years of data, there were relatively few deaths in some categories of exposure. We may have underestimated the risk of ESKD as the study cohort included individuals whom may have reached ESKD but did not receive renal replacement therapy (conservative care). We categorized BP measures at clinically relevant cut points and did not explore possible nonlinear associations with outcomes. Our study cohort includes a referred group of patients from a distinct geographic region that may limit generalizability. BP was measured once per visit which is reflective of real world practice but may not be as accurate as the average of multiple readings. Last, our findings require validation in other study cohorts.
Perspectives
Different methods of quantitating longitudinal BP yields different information about late-stage CKD patients risk of ESKD or all-cause mortality. Elevations of SBP >160 mm Hg and DBP >85 mm Hg were associated with a higher risk of ESKD. SBP <120 mm Hg and cumulative exposure to SBP >140 were associated with all-cause mortality. An elevation of SBP or DBP from baseline is associated with a higher ESKD risk, a novel finding that may be represent potential therapeutic targets of intervention. These findings demonstrate the importance of considering the longitudinal course of BP for determining the risk of adverse events in patients with late-stage kidney disease.
